TriangleDISEASE & TREATMENT SETTING
INLYTA: advanced Renal cell carcinoma (first-line)
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
• in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Broader topic: Renal Cell Cancer
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- first-line
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for INLYTA (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice